thymosin alpha 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
==== A-ring reductases (5alpha- and 5beta-reductases) ==== Cortisol is also metabolized irreversibly into 5-alpha tetrahydrocortisol (5-alpha THF) and 5-beta tetrahydrocortisol (5-beta THF), reactions for which 5-alpha reductase and 5-beta-reductase are the rate-limiting factors, respectively. 5-Beta reductase is also the rate-limiting factor in the conversion of cortisone to tetrahydrocortisone.
=== Depression === A comparative meta-analysis of 21 major antidepressants found that venlafaxine, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, and vortioxetine were more effective than other antidepressants, although the quality of many comparisons was assessed as low or very low. Open-label evidence also suggests potential benefit in treatment-resistant cases: in a multicenter Canadian study of adults with inadequate response to prior antidepressants (n=159), 58% achieved response and 28% remission after 8 weeks of venlafaxine (mean 260 mg/day); tolerability was generally acceptable. Venlafaxine was similar in efficacy to the atypical antidepressant bupropion; however, the remission rate was lower for venlafaxine. In a double-blind study, patients who did not respond to an SSRI were switched to either venlafaxine or another SSRI (citalopram); similar improvement was observed in both groups. Studies have not established its efficacy for use in pediatric populations. In children and adolescents with depression, venlafaxine increases the risk of suicidal thoughts or attempts. Higher doses (e.g., 225 mg and 375 mg per day) of venlafaxine are more effective than lower doses (e.g., 75 mg per day) but also cause more side effects. Studies have shown that the extended-release is superior to the immediate-release form of venlafaxine. A 2017 meta-analysis has shown that the efficacy of venlafaxine is not correlated with baseline severity of depression.
== Mechanism of action == The mechanism seems to vary with different organisms and is not well understood. However, pentamidine is suspected to work through various methods of interference of critical functions in DNA, RNA, phospholipid and protein synthesis. Pentamidine binds to adenine-thymine-rich regions of the Trypanosoma parasite DNA, forming a cross-link between two adenines four to five base pairs apart. The drug also inhibits topoisomerase enzymes in the mitochondria of Pneumocystis jirovecii. Similarly, pentamidine inhibits type II topoisomerase in the mitochondria of the Trypanosoma parasite, resulting in a broken and unreadable mitochondrial genome.
He even tried, through Darío Gutiérrez (his deputy as ambassador in Paris) to accuse the Peruvian Foreign Ministry of being the true instigator of the incidents. Evo Morales, who has had an ambiguous position with the Peruvians during his government, going from promoting a highland brotherhood between both peoples of an indigenous nature, to having positions against Peru due to ideological differences, where relations almost broke during the government of Alan García for his meddling in the internal affairs of Peru, where the Minister of Foreign Affairs of Peru, José Antonio García Belaúnde, accused him of having anti-Peruvian positions even before he was president of Bolivia and of that there is an attempt by Evo to make a historical revisionism to blame Peru for Bolivia's problems, such as its condition as a landlocked country, these strategies of Morales would have sought to replace the anti-Chilean discourse of the outlet to the sea, referring to the use of nationalism for populist purposes of internal politics (since many of these actions were prior to elections that determined their political future).
== Society and culture == Some commentators argue that skin cancer surgery, including Mohs surgery, is overutilised as rates of skin cancer surgery are increasing worldwide. It is unclear if this relates to higher rates of skin cancer, increased vigilance in diagnosis, and increased availability of the procedure, or patient and doctor preferences. The incidence of Mohs surgery increased significantly over the decade between 2004 and 2014. In a sample of 100 Mohs surgeries, the total cost ranged from US$474 to US$7,594, with the higher costs for hospital-based complex procedures. In Australia, the direct out of pocket cost to patients may vary from $0 to $4000. When the non-Mohs surgery is performed by multiple doctors including pathologists the costs may be increased further. This is especially true when the cancer is incompletely excised and requires repeat surgery.
Sources: en.wikipedia.org
=== Korea === Either dried kombu powder or julienned kombu (typically of the species Saccharina japonica) can be used to make the tea. Powdered tea can be made by pan-frying and pounding cleaned and dried kelp. For a cup of hot water, two to three spoons of kelp powder is used. Optionally, sugar or honey can be added. Alternatively, around 30 grams (1.1 oz) of cleaned kelp pieces are infused in 300–500 millilitres (11–18 imp fl oz; 10–17 US fl oz) of hot water. The kelp slices are removed after infusing, and salt is added to taste.
1 November The Foreign Office reports that the departure of British nationals from Gaza will likely take place "in stages over the coming days." The BBC reports that 200 are believed to be in the region. The 2023 AI Safety Summit takes place at Bletchley Park. The UK government announces a "world first agreement" between 28 countries on how to manage the riskiest forms of AI. Gail Bradbrook, a co-founder of Extinction Rebellion, is convicted of causing £27,000 of damage to the Department for Transport at a demonstration in 2019. Figures published by Nationwide Building Society indicate a 0.9% rise in house prices in October, the largest for a year, which Nationwide says was likely due to demand being greater than availability of properties for sale. The 2024 British Soap Awards are cancelled for an undisclosed reason. Storm Ciarán hits Great Britain, bringing winds of up to 100 mph and widespread disruption. 2 November The Bank of England keeps interest rates unchanged at 5.25% for a second consecutive month. The Beatles release "Now and Then", likely the band's last ever song, featuring restored vocals by John Lennon (1940–1980), as well as guitar tracks by George Harrison (1943–2001), based on a home demo recorded by Lennon in the late 1970s. The sale of tickets for the 2024 Glastonbury Festival is delayed for two weeks "out of fairness" to customers who did not realise their registration had expired. 3 November Jordan McSweeney, the killer of Zara Aleena, wins a Court of Appeal challenge to have his minimum sentence of 38 years reduced to a minimum of 33 years.
=== Drug discovery === One major outcome of research on human genes and proteins has been the identification of potential new drugs for the treatment of disease. This process relies on genome and proteome information to identify proteins associated with specific diseases, which can then be evaluated as therapeutic targets using computational approaches. For example, when a protein is implicated in a disease, knowledge of its three-dimensional structure can guide the design of drugs that interfere with its function. A molecule that fits into the active site of an enzyme but cannot be released can effectively inactivate the enzyme. This principle underlies many modern drug-discovery strategies, which aim to identify compounds capable of modulating or inhibiting disease-relevant proteins. As genetic differences among individuals are increasingly characterized, these approaches are expected to support the development of personalized medicines tailored to improve efficacy for individual patients. A branch of proteomics known as chemoproteomics provides a broad set of tools and techniques for identifying and characterizing the protein targets of drugs, thereby supporting drug discovery and development efforts.
According to the Federal Office for Radiation Protection, the few available results from investigations in the frequency range of active whole-body scanners that work with millimeter wave or terahertz radiation do not yet allow a conclusive assessment from a radiation protection perspective (as of 24 May 2017). In the vicinity of the plant, where employees or other third parties may be present, the limit value of the permissible annual dose for a single person in the population of one millisievert (1 mSv, including pregnant women and children) is not exceeded, even in the case of permanent presence. In the case of X-ray scanners for hand luggage, it is not necessary to set up a radiation protection area by Section §19 RöV, as the radiation exposure during a hand luggage check for passengers does not exceed 0.2 microsievert (μSv), even under unfavorable assumptions. For this reason, employees involved in baggage screening are not considered to be occupationally exposed to radiation in accordance with Section §31 X-ray Ordinance and therefore do not have to wear a dosimeter.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Aliquots are typically frozen well below zero Celsius and thawed only once, since repeated cycles promote aggregation and loss. Dilution into a neutral buffer limits degradation during short working periods, and prolonged storage at room temperature is avoided.